Cognitive Function and Quality of Life in People with MS Treated with Cladribine Tablets
In the CLARIFY-MS Extension study, 68.6% of 280 participants showed no or minimal cognitive decline after 48 months. Additionally, significant improvements in quality of life were reported over the same period, and the benefits of Cladribine on relapses and disability progression from the original study continued without unexpected safety issues.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Limited
- Outcome
- Not reported
Why it matters
These findings suggest that Cladribine treatment may help maintain cognitive function and improve the quality of life for individuals with relapsing multiple sclerosis.
What this does not prove
No new Cladribine treatment was administered during the Extension as per the EU label requirements, limiting the ability to assess ongoing treatment effects.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-20
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
Supporting passages (6)
study designCLARIFY-MS Extension study
findingsRESULTS: Overall, 68.6% of the participants (n = 192/280) showed no or minimal decline in cognitive function at M48 versus Parent study baseline. Significant improvements in Multiple Sclerosis Quality of Life-54 scores were observed over 48 months. The beneficial effect of CladT on relapses, radiological activity and disability progression observed in the Parent study were sustained during Extension. No unexpected safety signals were detected.
publication datePublication date: 2026-09-20
limitationsTitle: Cognitive resilience and improvements in health-related quality of life over 4 years in people with relapsing multiple sclerosis treated with cladribine tablets: Results from the CLARIFY-MS Extension study.
peer reviewedPublication types: Journal Article
subjectsTitle: Cognitive resilience and improvements in health-related quality of life over 4 years in people with relapsing multiple sclerosis treated with cladribine tablets: Results from the CLARIFY-MS Extension study.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.